Proprietary delivery platform, based on endogenous human cholesterol transport, offers the potential to enable novel medicines across a broad range of modalities and therapeutic areas.
New funding raised from life sciences investor Research Bridge Partners.
AUSTIN, TEXAS, August 20, 2023 – Qana Therapeutics announced a new fuding round today with a vision to advance its proprietary delivery platform to unlock the potential of novel medicines across a wide range of modalities and therapeutic areas. Qana’s delivery platform is based on research conducted in the laboratories of inventors Andras Lacko, of UNT HSC in Ft. Worth, TX and Alan Remaley of the NIH.